Listed

Celularity Inc: Form 10-Q for the period ended Mar 31, 2022

Filed with the SEC on May 16, 2022 and accepted by EDGAR at May 16, 2022, 16:39 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-01-01 to 2022-03-31$5.9mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Gross profit3 months2022-01-01 to 2022-03-31$1.9mus-gaap:GrossProfit
Research and development3 months2022-01-01 to 2022-03-31$21.7mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2022-01-01 to 2022-03-31$16.5mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2022-01-01 to 2022-03-31−$41.6mus-gaap:OperatingIncomeLoss
Net income3 months2022-01-01 to 2022-03-31−$62.9mus-gaap:NetIncomeLoss
Operating cash flow3 months2022-01-01 to 2022-03-31−$34.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2022-01-01 to 2022-03-31$1.5mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-03-31$48.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-03-31$75.7mus-gaap:AssetsCurrent
Total assetsAt period end2022-03-31$434.2mus-gaap:Assets
Current liabilitiesAt period end2022-03-31$26.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-03-31$344.3mus-gaap:Liabilities
Shareholders' equityAt period end2022-03-31$89.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-22-020422. Last ingested by Listed: Nov 11, 2026, 02:51 ET. Listed shows no prices and gives no investment advice.